ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2663

A Variant in the Osteoprotegerin Gene Is Associated with Coronary Atherosclerosis in Patients with Rheumatoid Arthritis: Results From a Candidate Gene Study

Cecilia P. Chung1, Joseph F. Solus2, Annette M. Oeser3, Chun Li4, Paolo Raggi5, Jeffrey R. Smith3 and C. Michael Stein3, 1Medicine, Vanderbilt University, Nashville, TN, 2Medicine, Vanderbilt Medical Center, Nashville, TN, 3Vanderbilt University, Nashville, TN, 4Biostatistics, Vanderbilt University, Nashville, TN, 5Emory University, Atlanta, GA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Atherosclerosis, coronary artery disease, genomics, inflammation and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects VII: Prediction of Outcome in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Patients with rheumatoid arthritis (RA) have accelerated atherosclerosis. However, this association is not fully explained by traditional cardiovascular risk factors or markers of inflammation. Little is known about the association between genetic variation and atherosclerosis in this population. Therefore, we examined the hypothesis that in patients with RA selected candidate gene variants were associated with the presence of coronary atherosclerosis.

Methods: One hundred and forty patients with RA, enrolled in an ongoing study to evaluate the prevalence and risk factors of coronary atherosclerosis in RA, were studied. Patients fulfilled the 1987 American College of Rheumatology classification criteria for RA and were 18 years or older. Coronary artery calcium (CAC), a non-invasive measurement of coronary atherosclerosis, was measured by electron beam computed tomography. Genotyping was performed using the Illumina Goldengate platform on a custom panel of 714 single-nucleotide polymorphisms (SNPs) tagging 176 selected candidate genes. Candidate genes were chosen for relevance to autoimmune and cardiovascular risk. The association between the presence of CAC and the allele frequency of the SNP was assessed by logistic regression models, adjusted for age, sex, and race. To adjust for multiple comparisons, a false discovery rate (FDR) threshold was set at 20%.

Results: Patients with RA were 54±11 years old and predominantly Caucasian (89%) and female (69%). The presence of CAC was detected in 70 patients (50%). After adjustment for age, race, and sex, SNPs in tumor necrosis factor receptor superfamily member 11 b (TNFRSF11B), matrix metalloproteinase-3 (MMP3), interleukin-12 (IL12), matrix metalloproteinase-9 (MMP9), nucleotide-binding oligomerization domain-2 (NOD2), C-reactive protein (CRP), myeloperoxidase (MPO), resistin (RETN), interferon regulatory factor (IRF) and Fcɣ receptor 2A (FCGR2A) were associated with the presence of CAC (Table). The variant rs2073618, which encodes an Asp3Lys missense change in the osteoprotegerin gene (OPG, TNFRSF11B), was significantly associated with CAC (OR= 4.09, p=0.00026) after FDR correction.

Table: Genetic Association with Coronary Atherosclerosis in Patients with RA

SNP

Gene

Major, minor allele

Minor allele frequency

Odds ratio* (95% CI)

p-value

rs2073618

TNFRSF11B

G,C

0.36

4.09 (1.93-8.70)

<0.001

rs522616

MMP3

T,C

0.29

4.43 (1.77-11.10)

0.001

rs2853694

IL12B

T,C

0.29

3.09 (1.53-6.24)

0.002

rs3918249

MMP9

T,C

0.49

0.36 (0.18-0.69)

0.002

rs17576

MMP9

A,G

0.45

0.34 (0.17-0.68)

0.002

rs3918253

MMP9

C,T

0.28

0.38 (0.20-0.72)

0.003

rs2274756

MMP9

G,A

0.16

0.24 (0.09-0.64)

0.004

rs751271

NOD2

T,G

0.49

2.57 (1.33-4.96)

0.005

rs650108

MMP3

G,A

0.41

2.82 (1.29-6.17)

0.009

rs1800947

CRP

C,G

0.04

5.93 (1.43-24.71)

0.014

rs9562414

TNFSF11

A,G

0.06

0.25 (0.08-0.79)

0.019

rs2107545

MPO

T,C

0.26

0.42 (0.20-0.89)

0.023

rs3745367

RETN

G,A

0.39

0.45 (0.22-0.91)

0.026

rs10954213

IRF5

G,A

0.47

0.50 (0.27-0.94)

0.030

rs633137

TNFSF11

T,A

0.08

0.34 (0.13-0.91)

0.031

rs2243828

MPO

A,G

0.23

0.43 (0.20-0.96)

0.040

rs1801274

FCGR2A

A,G

0.43

0.52 (0.28-1.00)

0.049

* Odds ratios for the comparison between minor and major allele.

Conclusion: Our results suggest that a potential functionally polymorphism of the TNFRSF11B gene, which encodes osteoprotegerin, is associated with the presence of coronary atherosclerosis in patients with RA. Replication of this finding in independent validation cohorts will be of interest.


Disclosure:

C. P. Chung,
None;

J. F. Solus,
None;

A. M. Oeser,
None;

C. Li,
None;

P. Raggi,
None;

J. R. Smith,
None;

C. M. Stein,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-variant-in-the-osteoprotegerin-gene-is-associated-with-coronary-atherosclerosis-in-patients-with-rheumatoid-arthritis-results-from-a-candidate-gene-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology